Seattle Genetics, Takeda deal

Seattle Genetics will receive $6 million in milestone payments from Takeda under a 2009 deal to co-develop lymphoma drug Adcetris brentuximab vedotin. The payment was triggered by the first commercial sale of Adcetris in Australia, South Korea and Mexico. Adcetris is approved in the countries to treat relapsed or refractory CD30-positive Hodgkin's lymphoma and systemic anaplastic large cell lymphoma (ALCL). Adcetris is now approved in 40 countries (see BioCentury, Dec. 21, 2009). ...